CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
Tomohiro Fujiwara(Okayama University), John H. Healey(Memorial Sloan Kettering Cancer Center), Andrew Chandler(Hospital for Special Surgery), Hiroshi Tazawa(Okayama University), Hiroya Kondo(National Cancer Centre Japan), Yildirim Dogan(Memorial Sloan Kettering Cancer Center), Alexander B. Christ(University of California, Los Angeles), Ouathek Ouerfelli(Memorial Sloan Kettering Cancer Center), Aki Yoshida(Okayama University), Toshiyoshi Fujiwara(Okayama University), Vinagolu K. Rajasekhar(Memorial Sloan Kettering Cancer Center), Guangli Yang(Sichuan University), Toshiaki Hata(Okayama University), Ed Purdue(Hospital for Special Surgery), Mohamed A. Yakoub(Hospital for Special Surgery), Malcolm A.S. Moore(Memorial Sloan Kettering Cancer Center), Toshifumi Ozaki(Okayama University)
Cited by 258
Related Papers
Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells
|Science|1986|1.2k
Tumor-suppressive <i>miR-34a</i> induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells
|Proceedings of the National Academy of Sciences|2007|902
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
|The Lancet|2019|472
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
|Journal of Clinical Oncology|2003|343
Osteosarcoma of the spine
|Cancer|2002|282